Kidney Patients Cite Insurance and Payment Issues as Top Barriers to FDA-Approved Treatment

Patients and Taxpayers Are Being Forced to Pick Up Currencies

Patent Voice Patient Choice ™ Campaign Engages Private Insurers and CMS

WASHINGTON, Oga. 15, 2022 /PRNewswire/ — The American Association of Kidney Patients (AAKP), the nation’s largest independent kidney patient advocacy organization, has unveiled a consumer awareness and campaign to encourage patients to use their commercial insurance plans with the Centers for Medicare and Medicaid Services. (CMS) for decisions that prevent patients from accessing new and safer products approved by the US Food and Drug Administration (FDA). The AAKP Patient Voice Patient Choice™ The campaign provides a successful, interactive way for patients, partners, and other stakeholders to identify and understand the barriers that affect care choices and timely access to new treatments ( The campaign includes strategies such as social media, letters to policyholders and shareholders, online petitions, Congressional outreach programs, and voter registration materials.

AAKP Patient Voice Patient Choice™

In United States, AAKP and kidney health professionals, along with bipartisan leaders in the US Senate and House of Representatives, have pushed to increase funding for kidney research and accelerate policies that remove barriers to drug reform. Over the past few years, the FDA has increased patient involvement, listened carefully to patient concerns, and approved many expected and safe advances in kidney care. The FDA’s approval has led to a major, renewed interest in kidney medicine among existing and new drug and medical device companies. The FDA’s approval has also created great hope among patients and families who suffer from high personal and financial costs due to kidney disease and related conditions such as diabetes, pruritus, and other debilitating diseases. Innovations approved include advanced dialysis technologies, including those used for home dialysis, which help patients gain independence, including the ability to pursue full-time and part-time work aspirations.

However, access to new kidney transplants has been severely limited by intentionally burdensome insurance and cost controls that prevent kidney doctors from providing the right care at the right time. These same payment systems often force high-risk patients and their caregivers to go through a long and difficult appeals process. Unfortunately, many of these complaints offer little hope for improvement, although there is clinical evidence to show that new treatments are more effective than those with kidney disease. Nationally, increasing patient frustration with insurers and barriers to timely access to care have fueled bipartisan DRM support for Price of HR3173 Improving Older Adults’ Timely Access to Caresponsored by the Congressional Kidney Caucus Co-Chair Representative Suzan DelBene (D-WA) and supported by the Caucus Co-Chair Larry Buckson (R-MU). AAKP also supports HR 3173. AAKP supports the efforts of Representatives DelBene and Bucson to increase care choices and opportunities for patients.

AAKP President Richard Knight, national kidney representative, he said, “The kidney patients and their allies have been working for years to bring new drugs to the market and end the disparity in care. They are not about to sit down if the payer policies and red tape prevent them from finding time to get treatment that prevents other suffering. or serious diseases AAKP has mobilized patient consumers and will raise their voices and vote to get insurers, elected officials, and other decision makers to be held accountable for their indifference to high-risk kidney patients.” At a June 14, 2022real events, The Hill Live: Chronic Kidney Disease – Developing Sustainable Patient Solutions, Knight and the AAKP thanked companies that have already listened to the concerns of kidney patients. Knight and the AAKP also called out Humana for its inaction on kidney disease patients and Humana’s byzantine policies that prevent chronic kidney disease (DKD) patients from getting adequate treatment that slows the progression of DKD.SEE HERE). Knight is a former dialysis patient, now a 16-year recipient, and a former US Congressional staffer and liaison to the Congressional Black Caucus.

Vice President of AAKP and Chairman of AAKP Veterans Health Initiative Edward V. Hickey, III, USMC, said, “The AAKP is deeply concerned that issues related to access are undermining the value of kidney medicine in the Kidney Decade. These issues are within the scope of the ongoing protections against waste of money that patients, taxpayers, and the whole country receives new treatment from patients who need it most. a permanent position.” Hickey is a former Administrative Assistant on Capitol Hill and participated in the first Congressional hearing on brain disease. He has served in two presidential administrations, including positions as liaison to veterans organizations, such as the Vietnam Veterans of America, AMVETS, Veterans of Foreign Wars, and the American Legion.

AAKP Chair of Policy and Global Affairs Paul T. Conwaya 42-year-old kidney transplant patient for the past 25 years, said, “Insurance coverage and federal payment options for new, state-approved, and safe kidney treatments are critical for private participation. If current payer policies fails to change, progress in kidney care is at risk, and patients and American taxpayers will continue to endure the avoidable and unnecessary complications of kidney disease and kidney failure. AAKP patient members and partners see this as unacceptable and are taking action .” Conway and Chief of Staff of the US Department of Labor and the US Office of Personnel Management, which administers the Federal Employees Health Benefits Program (FEHBP), a universal employer-sponsored health insurance program.

The Patient Voice Patient Choice ™ campaign is part of the AAKP Renal Decade start (, which was established in 2019. Its mission is to increase the involvement of kidney patients at home and abroad in decisions that affect disease research and the development of new innovations, including safe drugs, devices, and revolutionary technologies including kidney transplants and transplants. xenotransplants. For the past four years, AAKP, in collaboration with George Washington University School of Medicine and Health Scienceshe has also led International Conference on Kidney Diseasesone of the world’s largest patient-led conferences with participation from more than 80 countries. In June 2022, the European Kidney Health Alliance (EKHA) officially expanded the Kidney’s participation in the Decade of the Kidney™ by including it in its annual European Kidney Forum at Nyumba Law in Europe. Brussels. AAKP also runs the nation’s largest voter registration program, the The Kidney Water™ Program.

Kidney disease is a serious and growing problem for Americans and their families, with a high impact on minority, underserved and rural populations. The human and financial burden on patients, their families, and the American taxpayer is enormous. 37 million Americans are said to have kidney disease, and according to this study Centers for Disease Control (CDC), 90 percent of patients do not know that they are suffering from this disease. Kidney disease and kidney failure are a major burden on patients, families, and American taxpayers, and Medicare costs are only estimated $120 billion. Current kidney care is characterized by late diagnosis, outdated dialysis techniques, poor treatment options, long waits for transplants, and high mortality.

About the American Association of Kidney Patients (AAKP): Over the past decade, AAKP patients have helped achieve life-long medical care for kidney recipients (2020); new patient-centered policies through the White House Executive Order on Advancing American Kidney Health (2019); new job protections for organ donors from the US Department of Labor (2018); and Congressional legislation allowing HIV testing for HIV-infected patients (2013). AAKP’s virtual platforms and social networks are recognized worldwide for their impact. Follow AAKP on TV at @kidneypatient on Facebook and @ kidney disease patients on Twitter, I’m visiting for more information.

Jennifer Rate
Marketing & Communications Manager
(813) 400-2394

(PRNewsfoto/American Kidney Association)

(PRNewsfoto/American Kidney Association)



Check out the original to download the soundtrack:

SOURCE American Association of Kidney Diseases